Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
1. NBIX's study for NBI-1070770 did not meet primary efficacy endpoints. 2. The drug was generally well tolerated despite study results. 3. Neurocrine reported adjusted earnings of $2.17 per share, exceeding estimates. 4. Sales of $794.9 million topped Wall Street forecasts. 5. Stock price fell 2.64% following the study announcement.